LMAT 📈 LeMaitre Vascular - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5255582018

LMAT: Vascular Grafts, Catheters, Patches, Shunts, Biosynthetic Grafts, Medical Tapes

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. Web URL: https://www.lemaitre.com

Additional Sources for LMAT Stock

LMAT Stock Overview

Market Cap in USD 2,071m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 2006-10-19

LMAT Stock Ratings

Growth 5y 84.2%
Fundamental 63.9%
Dividend 62.7%
Rel. Strength Industry 1247
Analysts 4.1/5
Fair Price Momentum 107.43 USD
Fair Price DCF 38.54 USD

LMAT Dividends

Dividend Yield 12m 0.69%
Yield on Cost 5y 1.90%
Annual Growth 5y 10.49%
Payout Consistency 100.0%

LMAT Growth Ratios

Growth Correlation 3m 57.1%
Growth Correlation 12m 96.8%
Growth Correlation 5y 84.1%
CAGR 5y 22.19%
CAGR/Mean DD 5y 1.44
Sharpe Ratio 12m 1.46
Alpha 40.08
Beta 0.86
Volatility 34.68%
Current Volume 455.2k
Average Volume 20d 216.4k
What is the price of LMAT stocks?
As of December 21, 2024, the stock is trading at USD 92.12 with a total of 455,200 shares traded.
Over the past week, the price has changed by -8.51%, over one month by -10.81%, over three months by +2.56% and over the past year by +69.29%.
Is LeMaitre Vascular a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, LeMaitre Vascular (NASDAQ:LMAT) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 63.93 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LMAT as of December 2024 is 107.43. This means that LMAT is currently undervalued and has a potential upside of +16.62% (Margin of Safety).
Is LMAT a buy, sell or hold?
LeMaitre Vascular has received a consensus analysts rating of 4.10. Therefor, it is recommend to buy LMAT.
  • Strong Buy: 4
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for LMAT stock price target?
According to ValueRays Forecast Model, LMAT LeMaitre Vascular will be worth about 118.9 in December 2025. The stock is currently trading at 92.12. This means that the stock has a potential upside of +29.02%.
Issuer Forecast Upside
Wallstreet Target Price 98.8 7.2%
Analysts Target Price 67.9 -26.3%
ValueRay Target Price 118.9 29%